En savoir plus
In cancer treatment, non-invasive diagnosis can avoid complications of biopsy and other unfavorable impacts on patient's health. DNA, methylation, SNPs, miRNA, mRNA, protein, autoantibodies, metabolite, and Omics-based markers from remote media such as blood, plasma, and urine are emerging as noninvasive molecular markers with high specificity and sensitivity towards many cancers. In many instances, these markers are also emerging as next-generation personalized diagnostics and targets or therapeutics for personalized cancer treatment. This book classifies the available molecular tumor markers according to their principal characteristics and relative methodologies.
Table des matières
GENERAL. Overview of Gynecologic Cancers. Cytogenetic Early Markers in Gynecologic Cancers. BREAST CANCER. Early Biomarkers in Breast Cancer. Diagnostic and Prognostic Markers of Breast Invasive Lesions. Biomarkers for Early Detection of Familial Breast Cancer. DNA Methylation: An Epigenetic Marker of Breast Cancer Influenced by Nutrients Acting as an Environmental Factor. CERVICAL CANCER. Biomarkers for Early Detection of Cervical Cancer. Biomarkers in Cervical Cancer: DNA HR-HPV, p16INK4a, Ki-67, and RNA-m E6/E. Biomarkers of Nucleotide Metabolism in Cervical Cancer. OVARIAN CANCER. Noninvasive Early Biomarkers in Ovarian Cancer. Biomarkers in Ovarian Endometrioid Carcinoma. MUC16/CA125: A Candidate Tumor Marker for Diagnosis and Therapy in Ovarian Cancer. Role of He4 in the Management of Ovarian Cancer. UTERINE AND FALLOPIAN TUBE CANCERS. Biomarkers in Endometrial Cancer. Biomarkers in Uterine Mesenchymal and Mixed Malignant Tumors. Noninvasive Early Biomarkers in Fallopian Tube Carcinoma. VAGINAL AND VULVAR CANCERS. Biomarkers for Early Detection of Vaginal Cancers. Noninvasive Early Biomarkers for Vulvar Cancer.
A propos de l'auteur
Debmalya Barh, Mehmet Gunduz
